As Mark Butler starts leading the process of integrating the NDIS into his portfolio, the review has revealed that the program's pricing limits are out of step with broader market rates, in some cases exceeding them by up to 68 per cent.

Latest Video
New Stories
-
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News -
Neurizon announces global agreement with Elanco for the commercialisation of NUZ-001
July 2, 2025 - - Australian Biotech -
Prescient Therapeutics opens share purchase plan
July 2, 2025 - - Australian Biotech -
Amplia Therapeutics announces additional confirmed partial response recorded in ACCENT trial
July 2, 2025 - - Australian Biotech -
Island Pharmaceuticals announces the appointment of new chair
July 2, 2025 - - Australian Biotech